Revenue and profitability grew strongly in Q1 2026, led by specialty ingredients and robust demand in nutrition and defense. Major CapEx projects are on track, and full-year guidance is confirmed despite some cost pressures, with positive cash flow and a strong equity position.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.